Cosmo Pharmaceuticals (CMOP.F) Stock Overview
A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
CMOP.F Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Cosmo Pharmaceuticals N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 94.48 |
| 52 Week High | CHF 169.90 |
| 52 Week Low | CHF 55.00 |
| Beta | 1.44 |
| 1 Month Change | -40.22% |
| 3 Month Change | -29.23% |
| 1 Year Change | 50.47% |
| 3 Year Change | 54.89% |
| 5 Year Change | n/a |
| Change since IPO | -41.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| CMOP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -10.5% | -2.0% | -2.3% |
| 1Y | 50.5% | 19.3% | 13.3% |
Return vs Industry: CMOP.F exceeded the US Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: CMOP.F exceeded the US Market which returned 13.8% over the past year.
Price Volatility
| CMOP.F volatility | |
|---|---|
| CMOP.F Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CMOP.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CMOP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 325 | Giovanni Di Napoli | www.cosmopharma.com |
Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo’s AI technology, a GI Genius intelligent endoscopy system.
Cosmo Pharmaceuticals N.V. Fundamentals Summary
| CMOP.F fundamental statistics | |
|---|---|
| Market cap | US$1.57b |
| Earnings (TTM) | -US$4.18m |
| Revenue (TTM) | US$120.70m |
Is CMOP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMOP.F income statement (TTM) | |
|---|---|
| Revenue | €104.17m |
| Cost of Revenue | €53.62m |
| Gross Profit | €50.56m |
| Other Expenses | €54.16m |
| Earnings | -€3.61m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 20, 2026
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 48.53% |
| Net Profit Margin | -3.46% |
| Debt/Equity Ratio | 0.06% |
How did CMOP.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/24 14:03 |
| End of Day Share Price | 2026/03/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cosmo Pharmaceuticals N.V. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Estelle Bétrisey | Berenberg |
| Laura Hindley | Berenberg |
| Kerry Holford | Berenberg |